Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GR1802 in Seasonal Allergic Rhinitis
NCT06315426Phase 2Active, not recruiting
- Sponsor
- Zhixiang Jintai
- Start
- Mar 2024
- Primary completion
- May 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of telikibart in seasonal allergic rhinitis (SAR), sponsored by Zhixiang Jintai. Started Mar 2024; status: active, not recruiting.
02
Drugs
telikibart
03
Conditions
seasonal allergic rhinitis (SAR)
Beyond the preview
Go deeper on NCT06315426.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06315426.